Abstract #3395
Nasal MOG ameliorates MRI brain pathology in progressive EAE
Hilit Levy-barazany 1 , Daniel Barazany 1,2 , Lindsay Puckett 3 , Shani Kanfi 1 , Nofit Borenstein-Auerbach 1 , Kayong Yang 3 , Jean Pierre S Peron 3 , Howard L Weiner 3 , and Dan Frenkel 1,4
1
Department of Neurobiology, Tel Aviv
Unviersity, Tel Aviv, Israel,
2
CUBRIC
School of Psychology, Cardiff University, Cardiff,
United Kingdom,
3
Department of Neurology,
Center for Neurologic Diseases, Brigham and Women's
Hospital, Harvard Medical School, Boston, MA, United
States,
4
Sagol
School of Neuroscience, Tel Aviv, Israel
MS is an autoimmune disease of the CNS in which
pro-inflammatory processes that target self myelin lead
to demyelination. We have shown that EAE model in
non-obese diabetic mice leads to a chronic disease which
is followed by brain lesion development that can be
monitored by MRI. Here we examined whether immune
responses induced by nasal MOG treatment affect clinical
progression and demyelination in chronic progressive
EAE, and evaluated the effect of the treatment by DTI
and T1-Gd techniques. Our results demonstrate that MRI
can monitor treatment of ongoing disease in this model
for testing new therapies for MS.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
